---
document_datetime: 2026-01-26 15:39:53
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aspaveli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aspaveli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.913369
conversion_datetime: 2026-01-29 12:10:19.514007
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ASPAVELI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                              |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) | 11/12/2025                          | 15/01/2026                                  | SmPC and PL                      | Please refer to scientific discussion 'Aspaveli-H-C- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000248937                     | - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include treatment of adults and adolescents aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulopathy (IC- MPGN) for Aspaveli, based on interim results from study APL2-C3G-310; this is a randomized, placebo-controlled, double- blinded, multicenter study to evaluate the safety and efficacy of twice-weekly s.c. infusions of pegcetacoplan in patients diagnosed with C3G or primary IC-MPGN and results from Phase 2 study APL2-C3G-204, an open-label, randomized, controlled study to evaluate the efficacy and safety of pegcetacoplan in posttransplant recurrence of C3G or primary IC-MPGN. As a consequence, sections 4.1, 4.2, 4.8, 4.9, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.0 of the RMP is approved. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. Furthermore, the PI is brought in line with   |            |     | 005553-II-EMA/VR/0000248937'   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| Variation type IB / EMA/VR/0000312476 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 01/12/2025 | N/A |                                |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000290246    | B.IV.1.a Addition or replacement of a device which is not an integrated part of the primary packaging - B.IV.1.a.3 Spacer device for metered dose inhalers or other device which may have a significant impact on the delivery of the active substance in the product (e.g. nebuliser) - Accepted                                                                                                                                                                                  | 16/10/2025   | 15/01/2026   | SmPC and PL   | The SmPC sections 4.2 and 6.6 has been updated as follows: Addition of instructions and precautions to use the new commercially available on-body (abdominal) Class IIb medical device for subcutaneous infusion. The PL has been updated accordingly.   |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000275191 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                                                                                                     | 27/05/2025   | N/A          |               |                                                                                                                                                                                                                                                          |
| Variation type IB / EMA/VR/0000254588    | This was an application for a group of variations. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process | 22/04/2025   | N/A          |               |                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                     | of the active substance - B.I.b.1.b Tightening of specification limits - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA / | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, | 06/04/2025 | N/A | EMA/VR/0000258001 |

<div style=\"page-break-after: always\"></div>

|                            | batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release -   |                                                                                                                                                                                                                                                        |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248510 | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing pegcetacoplan remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |